CD22 as a Target for Hematological Malignancies and Autoimmune Diseases

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• CD22 is a B cell-specific inhibitory coreceptor crucial for immune homeostasis.
• Its unique properties make it a prime target for treating B cell-related disorders.

Purpose of the Study:

• To review CD22 molecular mechanisms and clinical advancements in targeted therapies.
• To explore the translational potential of CD22-targeted strategies, especially CAR-T cell therapy, for autoimmune diseases.

Main Methods:

• Systematic review of CD22 molecular mechanisms.
• Analysis of clinical data from CD22-targeted therapies including immunotoxins, ADCs, and CAR-T cells.

Main Results:

• CD22-targeted therapies have shown clinical success in hematological malignancies and autoimmune diseases.
• Dual-targeting approaches, such as CD19/CD22 CAR-T, enhance efficacy and reduce antigen escape.

Conclusions:

• CD22-targeted therapies, particularly CAR-T cell therapy, offer significant potential for both cancer and autoimmune disease treatment.
• Future research should focus on optimizing CD22-targeted strategies for broader clinical application.